Valion Bio shareholders approve 2.6M share equity plan expansion and multiple dilutive financings

Filed June 3, 2026 · Period ending May 28, 2026 · ~1 min read

Key Changes

• high

  Shareholders approved issuance of common stock from conversion of Series C Preferred Stock and warrants under December 2025 institutional investor agreement, representing significant potential dilution.

  Item 5.07: Annual Meeting Results verify on EDGAR →
• high

  Shareholders approved issuance of common stock from conversion of Senior Secured Convertible Note and warrant exercise for 3i, LP under December 2025 agreement, adding to dilution risk.

  Item 5.07: Annual Meeting Results verify on EDGAR →
• medium

  2021 Equity Incentive Plan expanded by 2,581,608 shares (82% increase from 3.1M outstanding shares), enabling additional stock-based compensation for employees and directors.

  Item 5.02: Compensatory Arrangements verify on EDGAR →